Exhibit 99.1
Actavis Pharma Segment Revenue
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (Unaudited; $ in millions) | | Three
Months
Ended
March 31,
2014 | | | Twelve
Months
Ended
December 31,
2013 | | | Three
Months
Ended
December 31,
2013 | | | Three
Months
Ended
September 30,
2013 | | | Three
Months
Ended
June 30,
2013 | | | Three
Months
Ended
March 31,
2013 | | | Twelve
Months
Ended
December 31,
2012 | | | Twelve
Months
Ended
December 31,
2011 | |
| | | | | | | | |
North American Brands: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Women’s Health | | $ | 212.6 | | | $ | 292.8 | | | $ | 224.6 | | | $ | 26.9 | | | $ | 21.3 | | | $ | 20.0 | | | $ | 61.9 | | | $ | 32.5 | |
Urology / Gastroenterology | | | 225.2 | | | | 408.8 | | | | 236.1 | | | | 60.2 | | | | 55.8 | | | | 56.7 | | | | 217.7 | | | | 209.0 | |
Dermatology / Established Brands | | | 156.2 | | | | 360.9 | | | | 174.4 | | | | 65.9 | | | | 67.7 | | | | 52.9 | | | | 198.6 | | | | 190.6 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
Total North American Brands | | | 594.0 | | | | 1,062.5 | | | | 635.1 | | | | 153.0 | | | | 144.8 | | | | 129.6 | | | | 478.2 | | | | 432.1 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
North American Generics | | | 1,024.2 | | | | 3,915.7 | | | | 1,033.1 | | | | 976.1 | | | | 949.8 | | | | 956.7 | | | | 3,472.2 | | | | 2,945.6 | |
International | | | 646.7 | | | | 2,502.5 | | | | 728.1 | | | | 576.8 | | | | 619.4 | | | | 578.2 | | | | 978.1 | | | | 430.5 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net Revenues | | $ | 2,264.9 | | | $ | 7,480.7 | | | $ | 2,396.3 | | | $ | 1,705.9 | | | $ | 1,714.0 | | | $ | 1,664.5 | | | $ | 4,928.5 | | | $ | 3,808.2 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Our North American Brands Revenue consists of three categories: Women’s Healh, Urology/Gastroenterology, and Dermatology/Established Brands. The products that make up each category are as follows:
| | | | | | |
Women’s Health | | Urology/Gastroenterology | | Dermatology/Established Brands |
| Atelvia® | | Androderm® | | Cordran® Tape | | Tri-Norinyl® |
| Crinone® | | Asacol® | | Doryx® | | Oxytrol® |
| Estrace® Cream | | Asacol® HD/Asacol® 800 | | Actonel® | | Gelnique® |
| Generess® Fe | | Delzicol® | | Actonel DR® | | Sodium Ferric Gluconate |
| Lo Loestrin® Fe | | Enablex® | | INFeD® | | Actigall® |
| Loestrin® 24 Fe | | Rapaflo® | | Kadian® | | Condylox® |
| Minastrin® 24 Fe | | Trelstar® | | Alora® | | Fioricet® |
| Fibristal™ | | AndroGel® Copromotion Revenue | | Brevicon® | | Fiorinal® |
| | | | ella® | | Norco® |
| | | | Estrace® Tablets | | Microzide® |
| | | | Femring® | | Femcon® Fe |
| | | | Norinyl® | | femhrt® |
| | | | Nor-QD® | | Sarafem® |
| | | | PapSure® | | Estrostep® Fe |
| | | | PreQue 10™ | | Ovcon® |
| | | | | | Royalty, Supply & Other Revenue |
